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Diabetic nephropathy (DN) is the most common cause of end-stage renal disease
worldwide. Blood glucose and blood pressure control reduce the risk of
developing this complication; however, once DN is established, it is only possi-
ble to slow progression. Sodium–glucose cotransporter 2 (SGLT2) inhibitors, the
most recent glucose-lowering oral agents, may have the potential to exert
nephroprotection not only through improving glycemic control but also through
glucose-independent effects, such as blood pressure–lowering and direct renal
effects. It is important to consider, however, that in patients with impaired renal
function, given their mode of action, SGLT2 inhibitors are less effective in lowering
blood glucose. In patients with high cardiovascular risk, the SGLT2 inhibitor
empagliﬂozin lowered the rate of cardiovascular events, especially cardiovascular
death, and substantially reduced important renal outcomes. Suchbeneﬁts onDNcould
derive from effects beyond glycemia. Glomerular hyperﬁltration is a potential risk
factor for DN. In addition to the activation of the renin-angiotensin-aldosterone sys-
tem, renal tubular factors, including SGLT2, contribute to glomerular hyperﬁltration in
diabetes. SGLT2 inhibitors reduce sodium reabsorption in the proximal tubule, caus-
ing, through tubuloglomerular feedback, afferent arteriole vasoconstriction and re-
duction in hyperﬁltration. Experimental studies showed that SGLT2 inhibitors
reduced hyperﬁltration and decreased inﬂammatory and ﬁbrotic responses of prox-
imal tubular cells. SGLT2 inhibitors reduced glomerular hyperﬁltration in patients
with type 1 diabetes, and in patients with type 2 diabetes, they caused transient
acute reductions in glomerular ﬁltration rate, followed by a progressive recovery
and stabilization of renal function. Interestingly, recent studies consistently
demonstrated a reduction in albuminuria. Although these data are promising, only
dedicated renal outcome trials will clarify whether SGLT2 inhibitors, in addition to
their glycemic and blood pressure beneﬁts, may provide nephroprotective effects.
Diabetes is a worldwide growing public health problem with high risks of severe
microvascular and macrovascular complications. Diabetic nephropathy (DN) is a
major burden among the chronic complications of diabetes, given that it affects
;30% of patients with diabetes. Indeed, DN is themost common cause of end-stage
renal disease in the U.S. (1) and worldwide. Known risk factors for DN include
hyperglycemia, hypertension, dyslipidemia, smoking, and obesity as well as ethnic,
familial, and genetic predispositions (2). Key clinical trials have demonstrated that
early interventions, especially those aimed at primary prevention, are by far more
effective and that it is only possible to slow progression once DN is established (2).
Thus, large intervention trials on the impact of long-term intensiﬁed glucose control
on chronic diabetes complications, both in type 1 and type 2 diabetes (2–6), have
documented the critical role of glycemic control in preventing the development
of early DN as well as in slowing its progression; the recent long-term follow-up
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results of the Action in Diabetes and Vas-
cular Disease: Preterax andDiamicronMR
Controlled Evaluation Post-Trial Observa-
tional Study (ADVANCE-ON) (6) have
strengthened the concept that optimal
glycemic control is effective in preventing
DN and, interestingly, in slowing progres-
sion. In contrast, the clinical trials with
renin-angiotensin-aldosterone system
(RAAS) blockade versus other antihyper-
tensive agents in primary prevention of
DN have provided conﬂicting results
and are confounded, when albuminuria
(urinary albumin excretion rate) is the
primary outcome, by the rapid but re-
versible decreases in urinary albumin
excretion rate and by the differences in
blood pressure control. Current conven-
tional therapies to prevent DN and slow
its progression, based on blood glucose
(2–6) and blood pressure control and
RAAS blockade (7–9), are only partially
effective, and a substantial residual risk
to develop end-stage renal disease still
remains (10). Thus, in addition to current
therapies, new therapeutic approaches
leading to additional risk reduction are
needed.
Among the most recent glucose-
lowering oral agents, the sodium–glucose
cotransporter (SGLT) 2 inhibitors have the
potential to exert nephroprotection
through improving glycemic control but
also through glucose-independent ef-
fects, such as blood pressure–lowering
and, possibly, some direct renal effects.
Interestingly, SGLT2 inhibitors also have
renal hemodynamic effects, including
reducing glomerular hyperﬁltration (11),
as well as inhibitory effects on the in-
ﬂammatory and ﬁbrotic responses of
proximal tubular cells to hyperglyce-
mia (12). The SGLT2 is localized to the
proximal tubule and is responsible for
;90% of the reabsorption of the glucose
ﬁltered by the kidney. In type 2 diabetes,
as a consequence of the increased glu-
cose ﬁltered load, there is an increased
expression of SGLT2 and an increased
reabsorption of glucose; this a maladap-
tive mechanism contributing to hyper-
glycemia (13,14). SGLT2 inhibition leads
to substantial glycosuria and reduction
in fasting and postprandial plasma glu-
cose levels, without stimulating insulin
secretion, and therefore without increas-
ing the risk of hypoglycemia. The main
nonglycemic effects include blood pres-
sure reduction and weight loss. Given
the mode of action, the glucose-lowering
efﬁcacy of SGLT2 inhibitors depends on
renal function and on plasma glucose
levels (15,16).
Several review articles, primarily in
nephrological journals (11,12,17–20),
have considered the potential nephro-
protective effects of SGLT2 inhibitors.
The present review will emphasize con-
siderations for the diabetologist, especially
in discussion of the use and limitations
of SGLT2 inhibitors in improving glu-
cose control in patients with chronic
kidney disease (CKD). In addition, this
review will summarize the data both in
experimental models and in humans on
the potential nephroprotective effects
of these agents, including important
new ﬁndings indicating major effects
of SGLT2 inhibitors on important renal
clinical event rates.
Glucose-Lowering Efﬁcacy of SGLT2
Inhibitors in Patients With CKD
Given their mode of action, which is
heavily dependent on the glucose ﬁl-
tered load and therefore on glomerular
ﬁltration rate (GFR) (15,16), the efﬁcacy
of SGLT2 inhibitors in reducing plasma
glucose is expected to be decreased
with decreasing renal function. Since
glucose-lowering agents for patients
with CKD stages 3 and 4 are limited
and frequently require dose adjust-
ments, the identiﬁcation of the cutoff
of estimated GFR (eGFR) below which
clinically signiﬁcant reductions in plasma
glucose cannot be achieved with SGLT2
inhibitors is crucial. On the basis of the
studies performed so far in patients
with CKD, these drugs should not be
started in patients with eGFR ,60 mL/
min/1.73 m2 and should be stopped
when eGFR is ,45 mL/min/1.73 m2.
In patients with eGFR 30–60 mL/min/
1.73 m2, dapagliﬂozin, on top of existing
antidiabetes treatments, did not signiﬁ-
cantly reduce HbA1c from baseline to
24 weeks (placebo20.32%, dapagliﬂozin
5 mg 20.41%, and dapagliﬂozin 10 mg
20.44%) and 104 weeks (21). However,
dapagliﬂozin induced a signiﬁcant re-
duction in body weight from baseline
(0.21 kg increase with placebo and
21.54 and 21.89 kg for the 5- and
10-mg dose, respectively). Also, sys-
tolic and diastolic blood pressure values
were signiﬁcantly decreased in patients
receiving dapagliﬂozin (26.73 and
22.91 mmHg for dapagliﬂozin 10 mg at
52weeks). The reasons for thediscrepancy
between the effects on blood glucose,
blood pressure, and body weight remain
unexplained.
In patients with similar eGFR (30–50
mL/min/1.73m2), canagliﬂozin signiﬁcantly
reduced HbA1c from baseline compared
with placebo over 52 weeks (0.05% in-
crease for placebo, 20.19% canagliﬂo-
zin 100mg,20.33% canagliﬂozin 300mg)
(22). The absolute reductions in HbA1c
with dapagliﬂozin and canagliﬂozin
were similar, and the reason for the lack
of efﬁcacy in the dapagliﬂozin study was
the substantial reduction in HbA1c in the
placebo arm. Canagliﬂozin also lowered
systolic blood pressure (25.5 mmHg,
canagliﬂozin 100 mg; 26.7 mmHg,
canagliﬂozin 300 mg) and diastolic blood
pressure (22.0 mmHg, canagliﬂozin
100 mg; 22.4 mmHg, canagliﬂozin
300 mg) and body weight.
Finally, in patients with eGFR 30–60
mL/min/1.73 m2, empagliﬂozin 25 mg
also signiﬁcantly reduced HbA1c com-
pared with placebo over 24 weeks (0.05%
increase for placebo, 20.37% empag-
liﬂozin 25 mg) (23). Empagliﬂozin 25 mg
decreased body weight (20.08 kg pla-
cebo, 20.98 kg empagliﬂozin) and both
systolic blood pressure (0.4 mmHg pla-
cebo, 23.9 mmHg empagliﬂozin) and
diastolic blood pressure (0.2 mmHg
placebo, 21.7 mmHg empagliﬂozin). In
this study, empagliﬂozin was also tested
in patients with stage 2 and stage 4 CKD.
Not surprisingly, empagliﬂozin was more
efﬁcacious in reducing HbA1c in patients
with stage 2 than stage 3 CKD, while it
was ineffective in patients with stage 4
CKD. Thus, these studies demonstrate
that in patients with eGFR of 30–60
mL/min/1.73 m2 the efﬁcacy of SGLT2
inhibitors in reducing HbA1c is less than
in patients with preserved GFR. More-
over, in patients with eGFR,45mL/min/
1.73 m2, SGLT2 inhibitors did not lower
HbA1c (21–23), and for this reason, discon-
tinuation is recommended when this
level of renal insufﬁciency is reached.
SGLT2 Inhibitors and Glomerular
Hyperﬁltration
Several decades ago, Brenner (24)
performed a series of seminal studies
demonstrating that in animal models
glomerular hyperﬁltration accompanied
by glomerular capillary hypertension is
a pathophysiological mechanism for ini-
tiation and progression of renal disease,
regardless of the nature of the initial
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renal injury. The hemodynamic hypoth-
esis offered important insights into ther-
apeutic approaches to slow progression
of CKD. Observations on glomerular hy-
perﬁltration as a maladaptive compen-
satory consequence of glomerular injury
encouraged the interest in hyperﬁltration
as a potential mechanism of initiation of
DN and therefore as a risk factor. Several
studies have analyzed the prognostic
role of hyperﬁltration in the develop-
ment of the early manifestations of DN,
with conﬂicting results (25–27). In part,
this is due to the signiﬁcant direct corre-
lation between glycemia and GFR, ren-
dering it difﬁcult to dissect the impact
of glycemia and of hyperﬁltration on
the development of DN. Indeed, while
some studies observed that patients
with glomerular hyperﬁltration have in-
creased risk of fast GFR loss, others did
not conﬁrm these ﬁndings (25–27).
The two most important pathophysi-
ological mechanisms leading to renal
hyperﬁltration in diabetes are glomeru-
lar hemodynamic abnormalities due to
neurohormonal activation and tubular
factors. Thehemodynamic/neurohormonal
hypothesis is based on changes in affer-
ent and efferent arteriolar tone, result-
ing in glomerular hyperﬁltration, mostly
due to RAAS activation. The tubular hy-
pothesis is based on the fact that hyper-
glycemia causes an increase in proximal
tubule glucose ﬁltered load in diabetes.
This results in overactivity of SGLT2
and SGLT1 and consequent increased
tubular reabsorption of glucose and so-
dium and downstream activation of the
tubuloglomerular feedback system (28–
31). This increased proximal sodium
reabsorption leads to decreased sodium
delivery to and transport in the cells of
the macula densa, with consequent re-
duction in ATP breakdown and adeno-
sine production. Adenosine is a strong
vasoconstrictor, and its reduction causes
vasodilation of the afferent arteriole
and thus hyperﬁltration (32) (Fig. 1).
Abnormalities in the tubuloglomerular
feedback system have been described
in experimental models of diabetes
(28,29,33), and elegant micropuncture
studies have demonstrated the mecha-
nisms involved in the tubular hypothesis
(33). Increased proximal tubular sodium
reabsorption, with consequent reduction
in distal delivery, has also been demon-
strated in patients with type 1 or type 2
diabetes (30,31).
Studies in animal models have docu-
mented that increased glucose reab-
sorption in the proximal tubule is
related to an increased SGLT2 gene ex-
pression (13). In human tubular epithe-
lial cells grown from urines of patients
with type 2 diabetes (14), there is an
increase in the expression and glucose-
transport capacity of SGLT2 compared
with those from control subjects without
diabetes. Thus, SGLT2 inhibition should
result in an increased delivery of sodium
to the macula densa, a consequent in-
crease in adenosine release, resulting
in vasoconstriction of the afferent ar-
teriole leading to a reduction in renal
plasma ﬂow and GFR. Accordingly, in
SGLT2 knockout mice, the induction
of diabetes was associated with less
hyperﬁltration compared with wild-
type diabetic mice (34). Micropuncture
studies in rats with streptozotocin-
induced diabetes treated with SGLT2
inhibitors demonstrated reductions in
proximal sodium reabsorption and in
single nephron GFR (35).
On the basis of the encouraging ﬁnd-
ings in animal models, an interesting
study explored the effects of empagliﬂozin
on renal hemodynamics in 40 patients
with type 1 diabetes (36) without
chronic complications, with normal
blood pressure, not on antihyperten-
sive therapy, and with a GFR .60 mL/
min/1.73 m2. At baseline, 27 patients
had hyperﬁltration (GFR .135 mL/
min/1.73 m2) and 13 had normal GFR.
After 8 weeks of empagliﬂozin treat-
ment (as add-on to insulin) in patients
with baseline hyperﬁltration, there
was a reduction in GFR from 172 6
23 to 139 6 25 mL/min/1.73 m2, while
there was no effect in patients with nor-
mal baseline GFR (36). In association
with this 20% reduction in GFR, there
was a parallel reduction in renal plasma
ﬂow and increase in renal vascular resis-
tance, likely consequent of afferent
Figure 1—Tubuloglomerular feedback system in normal physiology (A), diabetes (B), and diabetes after treatment with SGLT2 inhibition (C). TGF,
tubuloglomerular feedback. Adapted from Cherney et al. (36).
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arteriolar vasoconstriction. In a subse-
quent publication (37), the data were
analyzed using the Gomez equation,
with estimates of intraglomerular pres-
sure and resistance of afferent and ef-
ferent arterioles; the data support the
idea that hyperﬁltration in diabetes is
predominantly due to afferent arteriole
vasodilation, with consequent increase
in intraglomerular pressure. The affer-
ent arteriole vasodilation was improved
with empagliﬂozin. The reduction in
GFR during empagliﬂozin treatment
was not mediated by the RAAS, as there
was an increase in both angiotensin II
and aldosterone levels as consequence
of the diuretic effect (36). This substan-
tial reduction in GFR (233 mL/min) ri-
vals that of similar patients during ACE
inhibition, suggesting that the magni-
tude of the hemodynamic effects of
SGLT2 inhibitors and RAAS blockers is
similar. Whether these hemodynamic
effects may translate to nephroprotection
remains an open question.
SGLT2 Inhibitors: Experimental Data
The most important structural changes
in type 1 diabetes occur in the glomeruli,
with thickening of the glomerular base-
ment membrane, mesangial expansion,
and podocyte injury; in the presence of
more advanced DN, however, there are
also important changes in the tubules
and interstitium with tubular atrophy
and interstitial ﬁbrosis and inﬂammation
(38). In contrast, among patients with
type 2 diabetes and microalbuminuria or
macroalbuminuria and preserved renal
function (39), a substantial proportion
(;40%) has advanced tubulo-interstitial
lesions despite only very mild glomerular
lesions. These lesions include thickening
and reduplication of tubular basement
membrane (especially of the proximal tu-
bules), tubular atrophy, interstitial ﬁbro-
sis, and chronic inﬂammation. When
proximal tubular cells are grown in high-
glucose conditions, there is an increased
secretion of inﬂammatory molecules and
proﬁbrotic cytokines (40). In vivo, this
leads to activation of inﬂammatory path-
ways, recruitment of macrophages, and
further tubular damage and interstitial ﬁ-
brosis. Among the candidate mediators,
transforming growth factor-b probably
plays a key role, promoting ﬁbrosis and
epithelial-to-mesenchymal transforma-
tion (41). The increase in glucose trafﬁck-
ing through the proximal tubular cells,
consequent of an increased transport
of glucose by SGLT2, could promote
inﬂammation and ﬁbrosis. In immor-
talized human proximal tubular cells,
empagliﬂozin reduced the glucose-
induced Toll-like receptor 2 and 4 and
nuclear factor-kB expression, both well-
known mediators of inﬂammatory and
ﬁbrotic responses in animal models of
DN (42). Thus, it is tempting to hypoth-
esize that in patients with type 2 diabetes
and tubulointerstitial lesions SGLT2 inhib-
itors might be particularly useful in re-
ducing tubulointerstitial ﬁbrosis and
inﬂammation.
However, considerable caution is
needed in extrapolating ﬁndings from
experimental models to human diabe-
tes, given that an animal model closely
reﬂecting DN in humans has not yet
been developed. Nevertheless, studies
performed in animals may provide inter-
esting insights, generating hypotheses
to be tested in persons with diabetes.
Numerous studies have been performed
exploring the effects of SGLT2 inhibitors
in animal models of DN. Overall, the
effects on renal hyperﬁltration are con-
sistent,while the effects on renal enlarge-
ment, inﬂammation, and injury differ,
underlying the different susceptibility
as well as the confounding effects of
different blood glucose levels in the
different animal models. In a short-term
study, Malatiali et al. (43) observed that
the nonspeciﬁc SGLT inhibitor phlorizin
reduced the increase in kidney size
and the glomerular hyperﬁltration in
streptozotocin-induced diabetic Fisher
rats. Different results have been ob-
served in streptozotocin-induced dia-
betic SGLT2 knockout mice, where
there was a reduction in hyperﬁltration
but not in renal hypertrophy and in
markers of inﬂammation or ﬁbrosis
compared with the wild-type diabetic
mice (34). As outlined above, data in
animal models often differ depending
upon the model used. Thus, when
streptozotocin-induced diabetic endo-
thelial nitric oxide synthase knockout
mice were treated with empagliﬂozin
there was no attenuation of albuminuria
(44) or improvement in renal lesions
or inﬂammatory markers (44). In con-
trast, the beneﬁcial effects of empagliﬂo-
zin on DN lesions were recently described
in normotensive BTBR ob/ob mice,
where reductions in glomerular hyper-
trophy, mesangial matrix expansion,
albuminuria, and markers of inﬂamma-
tion were observed (45).
In db/db mice, 12 weeks of treatment
with dapagliﬂozin decreased blood glu-
cose and prevented the increase in albu-
minuria (46). Interestingly, there was a
dose-dependent decrease in mesangial
expansion and interstitial ﬁbrosis (46) ac-
companied by reductions in macrophage
inﬁltration and the gene expression of
mediators of inﬂammation and oxida-
tive stress MCP-1, intracellular adhesion
molecule-1, osteopontin, and transforming
growth factor-b1.
Taken together, results in animal
models suggest that SGLT2 inhibition
has hemodynamic effects, attenuating
glomerular hyperﬁltration and reducing
albuminuria. As far as the effects on DN
lesions and on mediators of inﬂamma-
tion and ﬁbrosis, the results are conﬂict-
ing and highly variable depending upon
the different experimental models used
and the different glucose levels. It is thus
difﬁcult from these data to understand
whether these beneﬁcial effects are sim-
ply related to the reductions in blood
glucose and blood pressure or whether
there are additional and synergistic
direct protective renal effects.
SGLT2 Inhibitors and Renal Function
in Clinical Studies
The changes in GFR during SGLT2 inhibi-
tion are similar in patients with normal
renal function and in those with CKD.
The time course of changes in renal func-
tion is typically characterized by a rapid
decline in GFR during the ﬁrst weeks of
treatment, followed by a progressive re-
covery that is faster and more evident in
patients with normal renal function at
baseline. Studies performed in patients
with moderate renal impairment (21–
23) demonstrated signiﬁcant renal ef-
fects; thus, treatment with dapagliﬂozin
(104 weeks) (21), canagliﬂozin (26 weeks)
(22), and empagliﬂozin (52 weeks) (23)
resulted in an initial decrease in eGFR
with a trend toward an increase over
time (Figs. 2 and 3). In patients with
CKD stage 3, after 1 week of treatment
there was a reduction in eGFR (21) with a
progressive recovery of GFR during the
following weeks (Fig. 2). In a study where
patients with eGFR of 30–50 mL/min/
1.73 m2 were randomized to canagliﬂozin
or placebo for 26 weeks (22), a similar
eGFR course was observed. Finally, in
CKD stage 3, patients treatment with
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empagliﬂozin 25 mg reduced eGFR by
;4 mL/min at 12 weeks, with a slight re-
covery at 52 weeks. Interestingly, after
drug discontinuation GFR returned to
the baseline values, suggesting that the
decrease in GFR during treatment is he-
modynamic and not consequent of renal
injury (23).
In a large study where patients with
normal renal function were randomized
to canagliﬂozin or glimepiride on top
of metformin for 52 weeks (47), the
expected pattern of GFR course was
observed, with an initial fall followed
by stabilization. In contrast, there was
a progressive GFR fall in patients receiving
glimepiride (47).
A large pooled analysis of 12 random-
ized clinical trials of up to 24 (4,545
patients) or 102 (3,036 patients) weeks
explored the effects of dapagliﬂozin
on renal function in patients with
type 2 diabetes with normal or mildly
impaired renal function (48). Mean
eGFR showed small transient reductions
with dapagliﬂozin at week 1, which
returned to near baseline values there-
after. Mean eGFR changes were not sig-
niﬁcantly different for dapagliﬂozin 5
and 10 mg vs. placebo at 102 weeks:
22.52 and 21.38 vs. 21.31 mL/min/
1.73 m2, respectively (48).
In addition to the effects on GFR,
SGLT2 inhibitors also inﬂuence albumin-
uria. Table 1 summarizes the results
of SGLT2 inhibitors on albuminuria.
Additional recent data also support the
concept that SGLT2 inhibitors reduce
albuminuria. Thus, we observed a re-
duction in urinary albumin-to-creatinine
ratio (UACR) with dapagliﬂozin in pa-
tients with stage 3 CKD (21). In a recent
post hoc analysis of this study, we eval-
uated the effects of dapagliﬂozin on
UACR in patients with microalbuminuria
or macroalbuminuria at baseline; we
also examined whether changes in UACR
were independent of changes in HbA1c,
blood pressure, and eGFR (49). A re-
duction in UACR was evident from the
ﬁrst time point (week 1). At 104 weeks,
placebo-corrected reductions of 243.8%
and 257.2% in UACR were observed in
the dapagliﬂozin 5 and 10 mg groups, re-
spectively. After adjustment for changes
in blood pressure, HbA1c, and eGFR, the
UACR reductions were largely maintained,
suggesting an independent, direct renal
effect (49). By week 104, more patients
shifted to a lower UACR category versus a
higher UACR category in the dapagliﬂozin
groups.
Similar data have been reported in
patients with CKD stage 3 treated with
canagliﬂozin (22): UACR decreased by
30%, 21%, and 7.5% after 52 weeks of
treatment with canagliﬂozin 100 mg,
300 mg, and placebo, respectively. A
large pooled analysis in .3,000 sub-
jects, where UACR changes and pro-
gression were analyzed as part of a
cardiovascular report, described simi-
lar ﬁndings in patients treated with
canagliﬂozin (50) (Fig. 4). Finally, in a study
where patients with CKD stage 3 were
treated with empagliﬂozin 25 mg (23),
fewer patients on empagliﬂozin shifted
to a higher category of albumin-to-
creatinine ratio (14.2%) compared with
placebo (33.6%), and more patients
shifted to a lower category (60% with
empagliﬂozin vs. 30% with placebo).
A recent post hoc analysis of 458
microalbuminuric patients with type 2 di-
abetes participating in several clinical trials
with empagliﬂozin conﬁrms a signiﬁcant
reduction in UACR (51). Overall, these
studies consistently demonstrate a signiﬁ-
cant reduction in UACR during SGLT2
inhibition; this reduction occurs early
after treatment initiation and lasts, in the
longest trial, for up to 2 years. Given that
increasedUACR is an importantmanifesta-
tion of DN and a predictor of progression,
these data support a nephroprotective
effect of SGLT2 inhibitors.
The recently published BI 10773
(Empagliﬂozin) Cardiovascular Outcome
Event Trial in Type 2 Diabetes Mellitus
Patients (EMPA-REG OUTCOME) trial
(52) compared the effects of empagliﬂo-
zin with effects of placebo on cardiovas-
cular outcomes in patients with type 2
diabetes with high cardiovascular risk. In
the empagliﬂozin group, there was a sig-
niﬁcant reduction in the primary out-
come of a composite of cardiovascular
events, which included death from car-
diovascular causes, nonfatal myocardial
infarction, and nonfatal stroke. Speciﬁ-
cally, empagliﬂozin treatment was asso-
ciated with a reduction in the relative
risk for cardiovascular death of 38%, of
hospitalization for heart failure of 35%,
and of death from any cause of 32% (52).
The EMPA-REG OUTCOME trial analy-
ses of the secondary renal outcomes
have recently been presented at the
2015 meeting of the American Society
of Nephrology (C. Wanner, personal
communication) (53). Compared with
those receiving placebo, patients re-
ceiving empagliﬂozin experienced a 39%
reduction in the risk of new or worsening
nephropathy (deﬁned as a UACR .300
mg/g, doubling of serum creatinine with
Figure 2—Changes in eGFR over time in subjects with type 2 diabetes with moderate renal
impairment treatedwith placebo and dapagliﬂozin (DAPA) 5mg and 10mg. Adapted from Kohan
et al. (21).
Figure 3—Changes in eGFR over time in sub-
jects with type 2 diabetes with moderate
renal impairment treated with placebo and
canagliﬂozin 100 mg and 300 mg. CANA,
canagliﬂozin. Adapted from Yale et al. (22)
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an eGFR of 45 mL/min/1.73 m2 or less,
initiation of renal replacement therapy,
or death due to renal disease). When the
composite outcome of doubling of serum
creatinine, initiation of renal replacement
therapy, or death due to renal disease
was considered, the relative risk reduc-
tion in the empagliﬂozin group was
even more pronounced (46%). These
data provide strong support for a neph-
roprotective effect of SGLT2 inhibitors.
In addition to EMPA-REG OUTCOME
trial, there are several ongoing trials
with SGLT2 inhibitors with renal end
points.
CREDENCE (Canagliﬂozin and Renal
Events in Diabetes with Established Ne-
phropathy Clinical Evaluation [clinical
trial reg. no. NCT02065791]) is evaluat-
ing the effects of canagliﬂozin compared
with placebo on the time to the primary
composite end point of end-stage renal
disease, doubling of serum creatinine,
and cardiovascular death in a large num-
ber of patients with type 2 diabetes and
CKD stages 2 and 3 and proteinuria re-
ceiving the maximum dose of ACE inhib-
itors or angiotensin receptor blocker.
CANVAS (CANagliﬂozin cardioVascular
Assessment Study: A Study of the Ef-
fects of Canagliﬂozin on Renal End-
points in Adult Participants With
Type 2 Diabetes Mellitus) (clinical trial
reg. no. NCT01032629) (54) is exploring
(as secondary end point) the effects of
canagliﬂozin on progression of albumin-
uria in patients with previous cardiovas-
cular events.
These long-term trials with SGLT2 in-
hibitors in patients with diabetic kidney
disease, using hard renal primary end
points, are ongoing and will hopefully
further clarify whether these agents
confer nephroprotection.
Conclusions
Despite improvements in the manage-
ment of renal risk factors like hypergly-
cemia and hypertension, DN remains a
major health problem, and new thera-
peutic options are needed to reduce
the burden of renal disease in diabe-
tes. SGLT2 inhibitors are a new class of
glucose-lowering agents, with important
inﬂuences on risk factors for DN: im-
provement in glycemic control and re-
duction in both systolic and diastolic
blood pressure. SGLT2 inhibition is also
associated with weight loss and reduc-
tion in uric acid. Both high levels of uric
acid and obesity are risk factors for DN
and for progression of CKD (47); how-
ever, the inﬂuences on the kidney of
the reductions in body weight and uric
acid levels that are obtained with SGLT2
inhibitors are unknown. Preclinical and
clinical studies have shown that SGLT2
inhibitors have potentially beneﬁcial re-
nal hemodynamic effects, with reduction
of hyperﬁltration and intraglomerular
pressure. In clinical trials, a positive inﬂu-
ence on albuminuria has consistently
been documented. It needs to be consid-
ered, however, that these “potentially
nephroprotective” drugs are less effective
in improving glycemic control in patients
with impaired renal function. Thus, given
the experimental data, the clinical obser-
vations on glomerular hyperﬁltration and
on albuminuria, and the recent secondary
renal event analyses of EMPA-REG OUT-
COME trial, evidence is increasing that
these drugs have substantial nephropro-
tective effects.
Large long-term ongoing trials, using
hard renal end points, will hopefully
clarify whether SGLT2 inhibitors, above
and beyond their well-known effects of
glycemia and blood pressure, also have
positive inﬂuences on the development
and progression of DN.
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